Cargando…

Systematic investigation of chemo-immunotherapy synergism to shift anti-PD-1 resistance in cancer

Chemo-immunotherapy combinations have been regarded as one of the most practical ways to improve immunotherapy response in cancer patients. In this study, we integrated the transcriptomics data from immunotherapy-treated tumors and compound-treated cell lines to systematically identify chemo-immunot...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yue, Pattarayan, Dhamotharan, Huang, Haozhe, Zhao, Yueshan, Li, Sihan, Wang, Yifei, Zhang, Min, Li, Song, Yang, Da
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Journal Experts 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10543256/ https://www.ncbi.nlm.nih.gov/pubmed/37790509 http://dx.doi.org/10.21203/rs.3.rs-3290264/v1

Ejemplares similares

Genome-wide gain-of-function screening characterized lncRNA regulators for tumor immune response
por: Wang, Yifei, et al.
Publicado: (2022)

PGAM1 Inhibition Promotes HCC Ferroptosis and Synergizes with Anti‐PD‐1 Immunotherapy
por: Zheng, Yimin, et al.
Publicado: (2023)

Combination Chemo‐Immunotherapy for Pancreatic Cancer Using the Immunogenic Effects of an Irinotecan Silicasome Nanocarrier Plus Anti‐PD‐1
por: Liu, Xiangsheng, et al.
Publicado: (2021)

Case Report: An “Immune-Cold” EGFR Mutant NSCLC With Strong PD-L1 Expression Shows Resistance to Chemo-Immunotherapy
por: Zhao, Qian, et al.
Publicado: (2022)

Polyoxazoline‐Based Nanovaccine Synergizes with Tumor‐Associated Macrophage Targeting and Anti‐PD‐1 Immunotherapy against Solid Tumors
por: Matos, Ana I., et al.
Publicado: (2023)

Epigenetic strategies synergize with PD-L1/PD-1 targeted cancer immunotherapies to enhance antitumor responses
por: Chen, Xi, et al.
Publicado: (2020)

Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers
por: Yi, Ming, et al.
Publicado: (2021)

Reducing PD-L1 expression with a self-assembled nanodrug: an alternative to PD-L1 antibody for enhanced chemo-immunotherapy
por: Cai, Shuxian, et al.
Publicado: (2021)

Cutaneous squamous-cell carcinoma of the head-neck area refractory to chemo-radiotherapy: benefit from anti-PD-1 immunotherapy
por: Koukourakis, Ioannis M., et al.
Publicado: (2021)

iRGD synergizes with PD-1 knockout immunotherapy by enhancing lymphocyte infiltration in gastric cancer
por: Ding, Naiqing, et al.
Publicado: (2019)

Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal
por: Wang, Zhenqing, et al.
Publicado: (2021)

Hydroxyethyl Starch-Based Nanoparticles Featured with Redox-Sensitivity and Chemo-Photothermal Therapy for Synergized Tumor Eradication
por: Yu, Chan, et al.
Publicado: (2019)

BET inhibitor JQ1 enhances anti-tumor immunity and synergizes with PD-1 blockade in CRC
por: Wang, Huijin, et al.
Publicado: (2022)

Chemo-immunotherapy combination after PD-1 inhibitor failure improves clinical outcomes in metastatic melanoma patients
por: Vera Aguilera, Jesus, et al.
Publicado: (2020)

Bcl-2 Inhibition to Overcome Resistance to Chemo- and Immunotherapy
por: García-Aranda, Marilina, et al.
Publicado: (2018)

Nanoparticle-enhanced chemo-immunotherapy to trigger robust antitumor immunity
por: Liang, Jingjing, et al.
Publicado: (2020)

Anti-Invasive and Anti-Proliferative Synergism between Docetaxel and a Polynuclear Pd-Spermine Agent
por: Batista de Carvalho, Ana L. M., et al.
Publicado: (2016)

Investigation of single and synergic effects of NLRC5 and PD-L1 variants on the risk of colorectal cancer
por: Catalano, Calogerina, et al.
Publicado: (2018)

Targeting tumor-associated macrophages to synergize tumor immunotherapy
por: Xiang, Xiaonan, et al.
Publicado: (2021)

Ultra-Hypofractionated Re-Irradiation with Anti-PD-1 Immunotherapy for Locoregionally Recurrent (after Radical Chemo-Radiotherapy) Non-Small Cell Lung Cancer
por: Filippatos, Konstantinos, et al.
Publicado: (2023)

SHP2 inhibition triggers anti-tumor immunity and synergizes with PD-1 blockade
por: Zhao, Mingxia, et al.
Publicado: (2019)

Recombinant cell-penetrating trichosanthin synergizes anti-PD-1 therapy in colorectal tumor
por: Zhang, Meng, et al.
Publicado: (2023)

High farnesoid X receptor expression predicts favorable clinical outcomes in PD-L1(low/negative) non-small cell lung cancer patients receiving anti-PD-1-based chemo-immunotherapy
por: Wang, Lina, et al.
Publicado: (2022)

The Future of Glioblastoma Therapy: Synergism of Standard of Care and Immunotherapy
por: Patel, Mira A., et al.
Publicado: (2014)

The need to optimize chemotherapy regimens for chemo-immunotherapy
por: Inamura, Kentaro, et al.
Publicado: (2022)

HHLA2 predicts improved prognosis of anti-PD-1/PD-L1 immunotherapy in patients with melanoma
por: Huang, Fu-xue, et al.
Publicado: (2022)

Chemo-immunotherapy by dual-enzyme responsive peptide self-assembling abolish melanoma
por: Wang, Yuhan, et al.
Publicado: (2023)

Immunotherapy Plus Radiotherapy for the Treatment of Sarcomas: Is There a Potential for Synergism?
por: Wang, Jiaqiang, et al.
Publicado: (2023)

High-dose ascorbic acid synergizes with anti-PD1 in a lymphoma mouse model
por: Luchtel, Rebecca A., et al.
Publicado: (2020)

Small-molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy
por: Zhu, Zhouting, et al.
Publicado: (2023)

Discovery of a novel dual-targeting D-peptide to block CD24/Siglec-10 and PD-1/PD-L1 interaction and synergize with radiotherapy for cancer immunotherapy
por: Shen, Wenhui, et al.
Publicado: (2023)

Establishing a panel of chemo-resistant mesothelioma models for investigating chemo-resistance and identifying new treatments for mesothelioma
por: Hudson, Amanda L., et al.
Publicado: (2014)

Dramatic response of metaplastic breast cancer to chemo-immunotherapy
por: Adams, Sylvia
Publicado: (2017)

A mathematical model for treatment using chemo-immunotherapy
por: Nave, Ophir
Publicado: (2022)

Chemo-Immunotherapy: A New Trend in Cancer Treatment
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2023)

Synergizing radiotherapy and immunotherapy: Current challenges and strategies for optimization
por: Rajeev-Kumar, Greeshma, et al.
Publicado: (2022)

Single-cell RNA sequencing to characterize the response of pancreatic cancer to anti-PD-1 immunotherapy
por: Zhou, Jing, et al.
Publicado: (2021)

Interface synergism and engineering of Pd/Co@N-C for direct ethanol fuel cells
por: Chang, Jinfa, et al.
Publicado: (2023)

Mate choice decision rules: Trait synergisms and preference shifts
por: Burley, Nancy Tyler, et al.
Publicado: (2018)

Precipitation of Autoimmune Diabetes With Anti-PD-1 Immunotherapy
por: Hughes, Jing, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_747l7rcffn5f69gkvnn10fmeje